All In Biotech

Free tool

FAERS Monitor: Opdivo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125554 or its brand name (Opdivo, Nivolumab). Reports on generic versions are filed under their own applications.

Reports

97,932

Serious

87,480

89% of reports

Hospitalization

39,754

Death reported

25,065

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death12,098
  • malignant neoplasm progression9,963
  • off label use6,485
  • diarrhoea5,336
  • fatigue4,264
  • pyrexia3,792
  • intentional product use issue3,329
  • nausea3,233
  • rash3,143
  • decreased appetite2,949
  • dyspnoea2,709
  • pneumonia2,499
  • colitis2,300
  • pneumonitis2,219
  • hypothyroidism2,155

Reports by year received

View as table
YearReports
20111
20125
201341
2014140
20152,615
20167,163
20179,632
201810,908
201911,341
20208,904
20219,407
202210,069
20237,721
20247,628
20256,915
20265,442

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,956,227 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal9,96323.022.6190,509
pneumonitisSignal2,21919.018.234,714
hypothyroidismSignal2,15515.514.827,230
colitisSignal2,30013.813.225,698
intentional product use issueSignal3,3298.48.221,098
deathSignal12,0983.03.017,076
decreased appetiteSignal2,9492.72.73,274
pyrexiaSignal3,7922.42.33,014
diarrhoea5,3361.81.71,872
pneumonia2,4991.71.6665
off label use6,4851.61.61,490
rash3,1431.61.5626
fatigue4,2641.21.1117
dyspnoea2,7091.01.02
nausea3,2330.90.858

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.